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Advancements in molecular biology have improved the ability to characterize disease-related nucleic
acids and proteins. Recently, there has been an increasing desire for tests that can be performed outside
of centralised laboratories. This study describes a novel isothermal signal ampliﬁcation cascade called
EzyAmp (enzymatic signal ampliﬁcation) that is being developed for detection of targets at the point of
care. EzyAmp exploits the ability of some restriction endonucleases to cleave substrates containing nicks
within their recognition sites. EzyAmp uses two oligonucleotide duplexes (partial complexes 1 and 2)
which are initially cleavage-resistant as they lack a complete recognition site. The recognition site of
partial complex 1 can be completed by hybridization of a triggering oligonucleotide (Driver Fragment 1)
that is generated by a target-speciﬁc initiation event. Binding of Driver Fragment 1 generates a completed
complex 1, which upon cleavage, releases Driver Fragment 2. In turn, binding of Driver Fragment 2 to
partial complex 2 creates completed complex 2 which when cleaved releases additional Driver Fragment
1. Each cleavage event separates ﬂuorophore quencher pairs resulting in an increase in ﬂuorescence. At
this stage a cascade of signal production becomes independent of further target-speciﬁc initiation events.
This study demonstrated that the EzyAmp cascade can facilitate detection and quantiﬁcation of nucleic
acid targets with sensitivity down to aM concentration. Further, the same cascade detected VEGF protein
with a sensitivity of 20 nM showing that this universal method for amplifying signal may be linked to the
detection of different types of analytes in an isothermal format.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The demand for technology capable of analyzing biological
analytes in the ﬁeld or at the point of care has grown in recent
years, with potential application in multiple ﬁelds including clin-
ical diagnosis, biosecurity, veterinary, agriculture, environmental
and food testing. Assays suitable for point of care testing should
ideally be sensitive, rapid, cost-effective and simple. Whilst im-
munoassays have been successfully applied at the point of care,
adaptation of nucleic acid testing remains a challenge. Speciﬁcally,
widely used target ampliﬁcation methods such as the polymerase
chain reaction (PCR) or loop mediated isothermal ampliﬁcation
(LAMP) bear high risk of target contamination, and PCR requires
complex instrumentation to allow rapid thermocycling (Notomi
et al., 2000; Saiki et al., 1988). Therefore, methods employingr B.V. This is an open access article
gh, Sydney, NSW 2015, Aus-
rdy).signal ampliﬁcation are being developed as alternatives.
In general, signal ampliﬁcation strategies involve a target re-
cognition step that triggers an enzymatic reaction and leads to
generation of a multitude of signal emitting probes (Gerasimova
and Kolpashchikov, 2014; Wang et al., 2014). Most methods have
been designed to run at a single temperature to simplify the
equipment necessary to run the reaction. One approach, which has
been exploited in many signal ampliﬁcation methods, relies on the
ability of nicking endonucleases (NEases) to recognize speciﬁc
nucleic acid sequences and cleave one strand of a duplex. These
methods generally require the target to form a nicking site either
by binding directly to a probe (Kiesling et al., 2007) or by facil-
itating formation of a nicking site between the probe and a
mediator (Hosoda et al., 2008; Kong et al., 2011; Song et al., 2014).
Although these strategies eliminate the risk of target contamina-
tion and the need for thermocycling, they possess other weak-
nesses. For example, the protocols based on nicking endonuclease
signal ampliﬁcation (NESA) requires the target to contain the
nicking enzyme restriction site (Kiesling et al., 2007) and this
limits the target regions which can be analyzed. It would beunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. (A)–(E) Elements of the EzyAmp cascade. (F) The observed rate constant (Kobs) of MnlI activity in the presence (red) or absence (black) of various bases of the Driver
Fragments (red underlined sequence) which result in completion of the partial MnlI recognition site present in complexes (i)–(vi) (blue sequences). (G) Fluorescence signal
corresponding to partial (blue), completed (red) and inhibited (green) complexes, in the presence or absence (black) of MnlI.
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sequences that could be detected; however, assay re-optimization
would need to be conducted every time. In addition, since the
sensitivity of such methods relies on the nicking of the probe
while leaving the target or the mediator intact, they are thus re-
stricted to using only NEases, of which there are only a few
commercially available (Hosoda et al., 2008; Kiesling et al., 2007;
Kong et al., 2011; Song et al., 2014).
Another strategy that is commonly used to improve detection
sensitivity utilizes a combination of NEases and polymerases to
exponentially create multiple trigger strands and subsequently
cause signal production (Connolly and Trau, 2011; Wang and
Zhang, 2012; Yin et al., 2013; Zhao et al., 2013). In these strategies,
the presence of target nucleic acids initiate extension of com-
plementary strands of provided DNA templates to create nicking
sites, which allow NEases to nick the newly synthesized strand.
The use of polymerases lacking 3′ exonuclease activity allows ex-
tension to continually occur from the nicked site, thus continued
production of this strand. These strategies hold great potential
since the displaced strand can be any DNA sequence, such as an
initiator for subsequent reactions or a reporter molecule. However,
they are often complex, and could suffer from non-speciﬁc ab initio
DNA synthesis in the absence of target as a result of containing
both a polymerase and endonuclease (Liang et al., 2006; Tan et al.,
2008). Further, when the nucleic acid target is used as the in-
itiating primer to create the nicking site, the system must be re-
optimized for every new target, and is limited to the detection of
only nucleic acids.
Herein, we report the development and application of EzyAmp
which is a novel enzymatic signal ampliﬁcation method utilizing
restriction endonucleases (REases) to drive an isothermal cascade
of oligonucleotide cleavage events that leads to signal production.
The method does not require the target to contain a restriction site
and it utilizes REases that cleave double stranded DNA, of which
there are many available with a large range of optimaltemperatures and reaction conditions. This leads to greater ﬂex-
ibility in assay design. The EzyAmp method allows rapid, sensitive
and quantitative detection of nucleic acids. Further, the cascade is
universal and as such requires minimal optimization for new tar-
gets and enables the detection of a variety of analytes including
nucleic acids and proteins.2. Experimental
2.1. Oligonucleotides and restriction endonuclease
All oligonucleotides were manufactured by Integrated DNA
Technologies (Coralville, IA, USA). Oligonucleotides used in each
experiment are speciﬁed in each method section, and their se-
quences and modiﬁcations are listed in Table S1. Some of the
oligonucleotides were labeled with ﬂuorophores and quenchers,
as indicated in their sequences, such that their cleavage by the
REase could be monitored as real-time ﬂuorescence signal. The
REase, MnlI, was obtained from New England Biolabs (Ipswich,
MA, USA).
2.2. Isothermal reaction method
Unless otherwise indicated, all reactions were conducted at
35 °C in a CFX96™ real-time PCR detection system (Bio-Rad). Re-
actions were performed in duplicate or triplicate in a ﬁnal volume
of 25 mL and results are presented as the average of the replicates
plotted using Microsoft Excel (Version 14).
2.3. Screening for MnlI cleavage activity on duplexes containing a
range of partial or nicked recognition sites
All EzyAmp oligonucleotide conformations are illustrated in
Fig. 1. Each duplex was composed of two Enzyme Ampliﬁer Signal
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form a partial complex containing only part of the MnlI recogni-
tion sequence (Fig. 1A). The partial site within this complex can be
completed by either the binding of a Driver Fragment (Fig. 1B) or
an Inhibitory Fragment (Fig. 1D) to form completed complexes
(Fig. 1C) or inhibited complexes (Fig. 1E), respectively.
A series of isothermal screening reactions were performed to
test the effect of placing the nick in different places in or around
the MnlI recognition sequence. These reactions containing 100 nM
of each EAS1 and EAS2 were incubated with 0.75 U of MnlI in 1X
NEB4 buffer and 100 mg/mL BSA (all from New England Biolabs).
Triplicate reactions were performed in the presence or absence of
100 nM of the relevant Driver Fragment. The oligonucleotide se-
quences of each EAS1, EAS2 and Driver Fragment combinations
that were tested are listed in Table S1. FAM ﬂuorescence was
measured 100 times at intervals of 30 s.
The observed rate constant (Kobs) of the isothermal screening
reactions above was calculated using GraphPad Prism 6 (GraphPad
Software) by ﬁtting the average ﬂuorescence against time to the
following equation Y¼Y0NS *exp(K*X)þNS; where Y is the
level of ﬂuorescence produced by the cleaved product at X time, Y0
was set to be less than the maximum ﬂuorescence (o5000), NS
was set to be greater than the level of background ﬂuorescence
(42500), and K is the Kobs. The values of all these Kobs in the
presence or absence of the relevant Driver Fragments for each
complex are plotted in Fig. 1F.
The results in Fig. 1G represent the triplicate reactions con-
taining either partial, completed or inhibited complexes. The
partial complex reaction contained 100 nM EAS1 (EAS1.1-TxR),
100 nM EAS2 (EAS2.1-TxR), 1X CutSmart™ buffer (New England
Biolabs) and 25 mM MgCl2 (Ambion). The completed complex
reaction contained the partial complex and 100 nM Driver Frag-
ment (DF1.1), and the inhibited reaction contained the partial
complex and 100 nM Inhibitory Fragment (Sub1i-FAM). Each
combination was incubated with or without 0.75 U of MnlI and
Texas Red ﬂuorescence was read 80 times at intervals of 60 s.
2.4. EzyAmp cascade initiated by target nucleic acids
2.4.1. Reaction under stringent buffer condition
The reactions plotted in Fig. 3B(i) were performed in duplicate
and contained 100 nM of each of EAS1 (EAS1.1_2-FAM), EAS2
(EAS2.1-FAM), EAS3 (EAS3.1-FAM) and EAS4 (EAS4.1-FAM),
300 nM of partzyme A (TL5A2/1), 150 nM of partzyme B (TL5B3/1),
30 nM of MNAzyme substrate (Sub1i-FAM) and 0.75 U MnlI in 1X
buffer pH 8.3 (10 mM Bis-Tris-Propane-HCl, 10 mM MgCl2, 1 mM
DTT (all from Sigma-Aldrich)), 100 mg/mL BSA and 10 mM MgCl2.
Reactions were initiated using various concentration (1 nM to
50 pM) of synthetic DNA target (AF-TL5), and the ﬂuorescence was
collected 125 times in the FAM channel at intervals of 60 s.
The standard curve in Fig. 3B(ii) was generated by plotting the
point of inﬂection (POI) values on the x-axis (corresponding to the
time when the slope of the curve was at maximum), against the
log of the target concentrations (1 nM to 50 pM) on the y-axis. The
coefﬁcients of variation (CV) were calculated for the replicates of
each target concentration.
2.4.2. Reaction under less stringent buffer condition
The reactions depicted in Fig. 3C were conducted in duplicate
and contained 100 nM of each of EAS1 (EAS1.1-FAM), EAS2
(EAS1.2-FAM), EAS3 (EAS3.1-FAM) and EAS4 (EAS4.1-FAM), 100 nM
of each of the three partzymes A (M13_3A2/1, M13_5A2/1, and
M13_7A2/1), 50 nM of each of the three partzymes B (M13_3B3/1,
M13_5B3/1, and M13_7B3/1), 80 nM MNAzyme substrate (Sub1i-
FAM) and 0.75 U MnlI in 1X NEB4, 100 mg/mL BSA and 10 mM
MgCl2. Reactions were initiated using various concentration (3 nMto 300 aM) of synthetic DNA target (AF-M13), followed by in-
cubation at 35 °C on the Agilent MX 3005 P qPCR System (Agilent
Technologies). Fluorescence was collected 60 times in the FAM
channel at 60 s intervals.
2.4.3. Reaction in two-step format
The reactions in Fig. 3D were conducted in duplicate. The initial
MNAzyme reaction contained 66.7 nM of each of the partzymes A
(18S_1A2/1, 18S_2A2/1, and 18S_3A2/1) and partzyme B (18S_1B3/
1, 18S_2B3/1, and 18S_3B3/1), 400 nM MNAzyme substrate
(Sub89-FAM), 50 nM MgCl2 and 50 nM Tris HCl pH 9.0 (Amresco).
Reactions were conducted in the presence or absence of total
human breast RNA (Biochain) in a total volume of 200 mL. The mix
was incubated at 50 °C for 1 h while shaking at 300 rpm. At the
end of the incubation, the mix was ﬁltered through a 10-kDa
Centrifugal Filter Unit (Merck Millipore) by spinning the tube at
14,000g at room temperature for 7 min. Eluate (5 mL) was then
added to the EzyAmp reaction mix containing 100 nM of each
EAS1 (EAS1.1-TxR), EAS2 (EAS1.2-TxR), EAS3 (EAS3.1-TxR), EAS4
(EAS4.1-TxR) and 0.75 U MnlI in 1x CutSmart™ buffer and 2 mM
MgCl2 to make a ﬁnal volume of 25 mL. The EzyAmp reaction was
then incubated at 35 °C and FAM ﬂuorescence was collected 80
times at 60 s intervals.
2.5. EzyAmp cascade initiated by VEGF detection
Recombinant human Vascular Endothelial Growth Factor
(VEGF) (R&D Systems) was reconstituted in 1X PBS (Amresco)
following the manufacturer's instructions. Reactions depicted in
Fig. 4A were conducted in duplicate with each mix containing
100 nM aptamer (VF_a) and 100 nM Initiator Driver Fragment 1
(VF_DF) in 25 mM Tris HCl pH 7.4 (Sigma-Aldrich), 150 mM NaCl
(Ambion) and 50 mM KCl (Sigma-Aldrich). The VEGF binding assay
was performed in 200 mL at 25 °C for 10 min while shaking at
300 rpm. The mix was then transferred to a 10 kDa Microcons
Centrifugal Filter Tube and centrifuged at 14,000g for 7 min. Fil-
trate (10 mL) was added to the EzyAmp mix containing 100 nM of
each EAS1 (EAS1.1-TxR), EAS2 (EAS2.1-TxR), EAS3 (EAS3.1-TxR),
and EAS4 (EAS4.1-TxR) in 1X CutSmart™ buffer with 0.75 U MnlI
and 5 mM MgCl2 in a ﬁnal volume of 25 mL. The EzyAmp reaction
was incubated at 35 °C in the CFX96™ Thermocycler, and Texas
Red ﬂuorescence was collected 200 times at 1 min intervals. The
standard curve in Fig. 4B was plotted according to the method for
the graph in Fig. 3B(ii) as outlined in Section 2.4.3. Results and discussion
3.1. Characterization of REase substrate requirements
The underlying principal of EzyAmp depends on the capacity of
oligonucleotide duplexes, which are initially resistant to REase
digestion, to be converted to functional REase substrates when a
speciﬁc target analyte is present. As such, signal generation asso-
ciated with REase cleavage is indicative of the presence of the
analyte. The resistance to digestion may be a consequence of ei-
ther the lack of sequence required for enzyme recognition and/or
due to the presence of additional sequence which blocks cleavage.
The analyte recognition step could either directly or indirectly lead
to generation of sequence which can complete the REase re-
cognition sequence and/or may lead to removal of a blocking
sequence.
Central to the development of EzyAmp was the discovery and
characterization of novel properties of REases. Preliminary ex-
periments aimed to discover whether these enzymes were capable
of cleaving substrates containing a nick within their recognition
Fig. 2. Schematic diagram of the EzyAmp isothermal signal ampliﬁcation cascade.
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analysis. This enzyme recognizes duplexes which contain 5′ CCTC
3′ and 3′ GGAG 5′ and cleaves 7 nucleotides and 6 nucleotides
away from this site (Brinkley et al., 1991). A number of partial
REase substrates were synthesized to each contain one Enzyme
Ampliﬁer Signal (EAS) oligonucleotide strand incorporating the
complete restriction site (EAS1) hybridized to a complementary
strand containing only a portion of the recognition sequence
(EAS2). An example of the partial substrate (partial complex) is
illustrated in Fig. 1A. The EAS oligonucleotides were labeled with a
ﬂuorophore and quencher such that cleavage by MnlI could be
monitored as changes in ﬂuorescence signal caused by the se-
paration of these moieties. An additional oligonucleotide, termed
the Driver Fragment, was synthesized to be complementary to
each partial complex to supply the missing bases of the full re-
cognition site. For example, the Driver Fragment of Fig. 1B com-
pletes the partial recognition site in the partial complex of Fig.1A.
The range of partial complexes was synthesized such that the re-
constituted recognition sites had a nick either within or adjacent
to the 5′ CCTC 3′ or 3′ GGAG 5′ sequences. Empirical screening was
conducted to ﬁnd the combinations of partial complexes and
Driver Fragments which resulted in cleavable substrates, termed
completed complexes (Fig. 1C), with further proviso that the pre-
sence of the Driver Fragment is absolutely required for cleavage.
Partial complexes were incubated with MnlI in the presence or
absence of the Driver Fragment (Fig. 1F). The observed rate con-
stant (Kobs) of cleavage was plotted for each complex and the value
was set to 0 in the absence of ﬂuorescence, indicating the lack of
cleavage. Three combinations of partial complex and Driver Frag-
ment did not result in structures where appreciable cleavage was
observed (Fig. 1F(i), (ii) and (vi)). Speciﬁcally, no cleavage was
detected when the nicks were located at C^CTC, CC^TC, and only very
low levels were observed for GGA^G (where ^ indicates the position
of the nick and underlined bases were present in the Driver
Fragment). Cleavage was observed when the nicks were located at
G^GAG, G^GAG and GG^AG (Fig. 1F(iii), (iv), and (v)); however, the
ﬁrst of the structures was also cleaved in the absence of the DriverFragment.
The nick site GG^AG resulted in the completed complex that was
the most efﬁciently cleaved and which required the Driver Frag-
ment for activity. This complex was then tested for its capacity to
be blocked by an overhang sequence. The partial complex was
hybridized to an Inhibitory Fragment, containing the Driver Frag-
ment and a non-complementary overhanging extension present at
the position of the nick (Fig. 1D). The partial complex and In-
hibitory Fragment together formed a complex termed an inhibited
complex (Fig. 1E). The partial, completed and inhibited complexes
(Fig. 1A, C and E respectively) were incubated with MnlI and
ﬂuorescence was plotted against time (Fig. 1G). The result showed
that while the partial complex by itself was resistant to MnlI di-
gestion, when combined with the Driver Fragment it formed a
cleavable completed complex; however, if the partial complex was
combined with the Inhibitory Fragment, it formed an inhibited
complex which had very little capacity to be cleaved. Since a
Driver Fragment could be generated from an Inhibitory Fragment
by removal of the non-complementary overhanging extension
sequence, this provides a strategy for conversion of an inhibited
complex to a cleavable completed complex. Overall, the study
identiﬁed various complexes which have properties useful in de-
veloping an EzyAmp cascade using MnlI.
The ability or inability to cleave partial, inhibited and com-
pleted-like complexes was also explored in a battery of other Type
II REases (data not shown). Some enzymes did not tolerate nicks
within the recognition site or they were able to cleave partial sites
present in partial complexes, at least with respect to those com-
binations of enzymes and nicks tested. Other enzymes which
could cleave the completed complexes displayed highly variable
cleavage efﬁciencies dependent upon the REase, the position of
the nick and the strand in which it was present. These experiments
highlight the necessity for empirical testing of REases to identify
those with properties useful for EzyAmp cascades since not all
enzymes possess them. To our knowledge there is only one pre-
vious study which reported a REase (PstI) being able to cleave a
duplex containing a nick within its recognition site (George, 1992).
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thermostable enzyme TspDTI. Characterization of this enzyme and
its application in an EzyAmp context is outlined in a separate
publication (manuscript in preparation).
3.2. Creation of EzyAmp isothermal signal ampliﬁcation cascade
The complexes and properties identiﬁed above were exploited
in an EzyAmp cascade where continuous formation and cleavage
of a pair of completed complexes lead to ampliﬁcation of a ﬂuor-
escence signal (scheme in Fig. 2). The initial components of the
EzyAmp cascade reaction would include only two partial com-
plexes and MnlI enzyme in buffer. Partial complexes 1 and 2 were
each designed to contain a Driver Fragment for the other partial
complex. These sequences only became functional Driver Frag-
ments once they were cleaved by MnII from the respective longer
oligonucleotides in which they were embedded. The EzyAmp
cascade could be triggered by the addition of an Initiator Driver
Fragment. In the ﬁrst step, the Initiator Driver Fragment 1 bound
to partial complex 1 and converted it into a cleavable completed
complex 1 (1a). Following cleavage of completed complex 1,
fragments of this complex would dissociate, resulting inFig. 3. MNAzyme-initiated EzyAmp cascade for the detection of nucleic acid targets. (A)
Driver Fragment 1. (B) Quantiﬁcation of nucleic acid target under a stringent reaction c
corresponding to the detection of 1 nM to 50 pM of target. (ii) Linear relationship betw
CVo5% except for the 600 pM reaction which had CV of 5.8%. (C) Fluorescence plot sh
2.4.2). (D) Fluorescence signal of the detection of 18S rRNA conducted in a two-step react
cascade following 1 h MNAzyme reaction.separation of the ﬂuorophore and quencher molecules and thus
signal production (2). This cleavage and dissociation would also
release a Driver Fragment 2 which when bound to partial complex
2, would complete the MnlI restriction site and create a cleavable
completed complex 2 (3). Cleavage by MnlI would result in dis-
sociation of the completed complex into fragments, producing
signal and releasing Driver Fragment 1 (4). The released Driver
Fragment 1 would then be able to bind to another partial complex
1 (5), and steps (1) to (5) would continue in a positive feedback
manner. Further, since the initiating and the released Driver
Fragments are not themselves cleaved or destroyed during the
reaction, they could be continuously re-cycled to form additional
new completed complexes throughout the reaction. In a separate
schema the reaction could be initiated by the addition of an In-
itiator Driver Fragment 2 (1b) and the cascade could then proceed
in a similar manner.
If the two partial complexes were labeled with different
ﬂuorophores, cleavage of each of completed complexes 1 and
2 could be monitored simultaneously to demonstrate that the
cascade occurred. Experiment with Texas Red-labeled partial
complex 1 and FAM-labeled partial complex 2 show generation of
both signals in the presence of either Initiator Driver FragmentSchematic illustration of target-dependent MNAzyme cleavage to produce Initiator
ondition (Section 2.4.1). (i) Fluorescence plot showing exponential signal increase
een the log of the target concentration and the signal at the POI. All reactions had
owing the limit of nucleic acid detection under a less stringent condition (Section
ion format (Section 2.4.3). Signal represents ﬂuorescence collected from the EzyAmp
Fig. 4. (A) Fluorescence signal representing the detection of 200–20 nM VEGF
protein using the aptamer-initiated EzyAmp cascade. The signal was plotted for the
cascade step which followed a 10 min protein binding step. (B) Linear relationship
between the log of VEGF concentrations and the signal at the POI, all duplicate
reactions had CVo10% except for the reactions containing 75 nM VEGF, which had
CV of 11.1%.
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tween the two complexes since conversions of both partial to
completed complexes could be triggered by either Initiator Driver
Fragments. In subsequent experiments, both partial complexes
were labeled with the same ﬂuorophore so that signal from both
completed complexes became cumulative.
3.3. Nucleic acid-dependent initiation of the EzyAmp cascade
3.3.1. Principle of initiation by MNAzymes
The EzyAmp cascade could provide a universal method for
amplifying signal and increasing the detection sensitivity of a wide
range of target analytes including nucleic acids and proteins
(Figs. 3 and 4, respectively). A multi-component nucleic acid en-
zyme (MNAzyme) (Mokany et al., 2010) can be used to trigger the
EzyAmp cascade to enable nucleic acid detection (scheme in
Fig. 3A). MNAzymes were previously engineered in our laboratory
by splitting the catalytic core of the 10–23 DNAzyme (Santoro and
Joyce, 1997) into two partial cores and appending target binding
arms to create half enzymes called ‘partzymes’. When used in the
EzyAmp cascade, the target directs assembly of the MNAzyme
which then cleaves universal MNAzyme substrates, producing
universal Initiator Driver Fragments, and these in turn can trigger
the EzyAmp cascade. The MNAzyme substrate and both partial
complexes were all labeled with the same ﬂuorophore so that the
ﬂuorescence increases along with all cleavage events during the
cascade
3.3.2. Analytical performance
To assess whether the EzyAmp reaction was quantitative, the
ability of the cascade to detect serial dilutions of a synthetic DNA
oligonucleotide target was analyzed (Fig. 3B(i)). The ampliﬁcation
plot showed a sigmoidal proﬁle over the range of 1 nM to 50 pM.
When the POI values were plotted against the log of the target
concentrations, a standard curve was generated that showed a
linear relationship with a correlation coefﬁcient of 0.99 (Fig. 3B
(ii)). To determine the detection limit of the MNAzyme-initiated
EzyAmp method, a second dilution series of synthetic DNAoligonucleotide target was analyzed in an alternative format
which had been optimized for speed and sensitivity. Using this
protocol, a low concentration of 300 aM target (4500 copies) was
detected within an hour (Fig. 3C).
The sensitivity and speciﬁcity achieved using the EzyAmp
method was dependent upon reaction conditions such as tem-
perature or oligonucleotide, enzyme and/or salt concentrations
(Fig. S2). For example, the background signal was suppressed
when reactions were performed in a sub-optimal buffer and with
less MNAzyme substrate (Fig. 3B(i)); however, these conditions did
not allow detection of the target concentrations lower than 50 pM.
In contrast, the assay was signiﬁcantly faster and more sensitive
when performed in optimal MnlI buffer and in the presence of
more MNAzyme substrate (Fig. 3C).
To demonstrate EzyAmp cascade performance in a complex
biological sample, experiments were performed to detect target
spiked into a background of human serum. Signal above back-
ground could be detected in samples containing 4% serum (Fig.
S3), suggesting the EzyAmp potential to be used with complex
clinical samples.
When the EzyAmp cascade was tested for the ability to detect
human genes and transcripts, we unexpectedly observed sponta-
neous activation of the MnlI EzyAmp cascade in the presence of
human genomic DNA or total RNA, even in the absence of MNA-
zymes. The mechanism of aberrant initiation of the MnlI system in
this situation is unknown. The observation is even more perplex-
ing when further experiments revealed that a second EzyAmp
cascade based on TspDTI was not spontaneously activated in the
same manner (data not shown). To circumvent this problem, a
two-step protocol was developed for analysis of rRNA. In the ﬁrst
step, the total RNA sample was incubated with MNAzymes tar-
geting a common housekeeping gene transcript, 18S rRNA. This
mix was then centrifuged through a ﬁlter designed to retain intact
MNAzyme substrates and total RNA whilst allowing cleaved sub-
strates (Initiator Driver Fragments) to pass through. The eluate was
tested for its ability to initiate the EzyAmp reaction, and the signal
observed indicated detection of the 18S rRNA directly from the
total RNA sample without the need for a reverse transcription step
(Fig. 3D). Assays for the detection of rRNA may have clinical utility.
For example, detection of rRNA transcripts was used to identify
bacterial pathogens associated with neonatal sepsis (Fujimori
et al., 2010). rRNA may also serve as a marker of malignancy since
expression levels have been reported to be signiﬁcantly upregu-
lated in many tumor cells (Uemura et al., 2012).
3.4. Protein-dependent initiation of the EzyAmp cascade
Signal ampliﬁcation methods following aptamer initiation have
been demonstrated for the detection of a variety of targets in-
cluding small molecules, amino acids or proteins (Kang et al.,
2015; Li et al., 2014; Wang et al., 2010; Xue et al., 2014). The
EzyAmp cascade was tested for its ability to detect protein targets
with the incorporation of an initial protein-aptamer binding step.
As a proof-of-principle for the current study, an aptamer which
has been previously selected for its afﬁnity with the human Vas-
cular Endothelial Growth Factor (VEGF) protein was chosen (Gold
and Janjic, 1998). An Initiator Driver Fragment 1 was designed to
form a partial duplex with this aptamer, such that binding of the
VEGF protein to the aptamer would displace the Initiator Driver
Fragment 1, which could then trigger the EzyAmp cascade (Fig.
S4). Since the optimal reaction conditions for VEGF-aptamer
binding differed from the EzyAmp cascade, the VEGF binding was
performed in a separate upfront step. Following protein binding,
the mix was ﬁltered through a centrifugal column so as to retain
the protein and bound protein-aptamer complexes, whilst per-
mitting any displaced Initiator Driver Fragment 1 to pass through
E.M. Linardy et al. / Biosensors and Bioelectronics 75 (2016) 59–66 65into the collection tube. The eluate was then used to initiate the
EzyAmp cascade. The result showed that using the EzyAmp cas-
cade, as little as 20 nM of the VEGF protein could be detected
(Fig. 4B).
This study demonstrates that REase properties on substrates
containing nicks or overhang sequences could be utilized to de-
velop the novel EzyAmp signal ampliﬁcation cascade. EzyAmp was
shown to be a versatile method for detection of multiple analyte
types, including nucleic acids and proteins, simply by linking the
cascade to a different initiation step. Several signal ampliﬁcation
methods have also been shown to have multi-analyte detection
capability (Bone et al., 2014; Liu et al., 2015; Wang et al., 2013).
However, these showed less sensitive nucleic acid detection (Liu
et al., 2015), or required hours to reach a similar level of sensitivity
(Wang et al., 2013). The EzyAmp cascade strategy, in contrast,
showed sensitive nucleic acid detection within an hour. This speed
and sensitivity was better than most other nucleic acid detection
methods (Connolly and Trau, 2011; Hosoda et al., 2008; Kiesling
et al., 2007; Li et al., 2008; Liu et al., 2015; Nakayama et al., 2008;
Yin et al., 2013; Zhang et al., 2014). Further, since the limit of de-
tection reported for the MNAzyme alone is 5 pM (Mokany et al.,
2010), this suggests the cascade has resulted in an approximate
104 fold ampliﬁcation of signal. Initial results for protein detection
using EzyAmp are promising; however improvement is needed to
reach the levels of sensitivity demonstrated by other aptamer-
based methods for VEGF detection (Freeman et al., 2012; Kwon
et al., 2010).
For analysis of both nucleic acid and protein targets, our on-
going studies are focused on reducing non-speciﬁc background
signal with the aim of increasing the sensitivity and speciﬁcity of
the EzyAmp cascade. The source of the background signal in the
absence of target analyte is hypothesized to be a consequence of
incomplete blocking of enzyme cleavage by the Inhibitory Frag-
ments within potential inhibited complexes (Fig. S5). Although our
data demonstrated that cleavage of the inhibited complex by MnlI
was very inefﬁcient, close inspection indicates a low level of
cleavage does occur overtime in a linear reaction (Fig. 1G). Thus,
any cleavage of the three possible inhibited complexes (Fig. S5) in
a cascade format could trigger the cascade and amplify this
background signal. One solution to overcome this would be to
provide a degree of separation by attaching any oligonucleotides
with the potential to function as Inhibitory Fragments to a solid
support and retain the rest of the components free in solution.
This would prevent formation of the inhibited complex. Following
MNAzyme or REase cleavage, the Driver Fragment sequences,
which were previously embedded within the attached oligonu-
cleotides, would be released into solution to drive the cascade.
This strategy may potentially increase the speciﬁcity and the
sensitivity as well as the speed of the reaction since the stringency
of the current reaction conditions, which helped to reduce the
background, could be relaxed.
There is considerable ﬂexibility for the ﬁnal format for the
EzyAmp cascade. While this current study monitors ampliﬁcation
by ﬂuorescence signal, the cascade could also be monitored by
alternative output signals such as electrochemical or colorimetric
changes. For example, components of an electrochemical reaction
could be tethered to the one of the oligonucleotides within a
partial complex. Formation and cleavage of a completed complex
could release these components, which would then generate
electrochemical signal. Alternatively if the partial complexes were
dual-labeled with gold nanoparticles, then cleavage could be
monitored as a change in color as the particles separated from one
another. Ongoing work in our laboratory aims to develop the
EzyAmp cascade in an attached format to improve its performance
and to explore speciﬁc medical applications for our technology.
Ultimately the proposed EzyAmp method has the potential to beextremely rapid and powerful since it utilizes multiple signal
ampliﬁcations steps through the use of (i) multiple turnover
MNAzymes, (ii) a feedback cascade, and (iii) optionally using a
backend redox reaction to further amplify the signal.4. Conclusion
This study describes previously unexplored properties of cer-
tain Type II REases in tolerating a nick and/or being inhibited by an
overhang sequence, both of which are present within the en-
zyme's recognition site. These properties were utilized in the
EzyAmp isothermal signal ampliﬁcation cascade, which was de-
monstrated to possess several advantages compared to other
methods. EzyAmp is a universal signal ampliﬁcation cascade that
can be linked to the detection of multiple analyte types via various
upfront target-speciﬁc methods such as MNAzymes for the de-
tection of nucleic acids or aptamers for the detection of proteins.
The method demonstrated highly sensitive detection of nucleic
acid targets, utilizes cheap and simple oligonucleotide compo-
nents and can be run under isothermal conditions. A limitation of
the present format relates to the eventual increase in background
signal, which we postulate may be decreased by tethering the
relevant components of the EzyAmp cascades.Acknowledgments
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